Chung et al. specifically demonstrated that PRMT5 inhibition reduces the recruitment of co-activators p300, MLL1, while enhancing the co-repressors HDAC2 and LSD1 in lymphoma cell lines. Here, PRMT5 is linked to lymphoma.